Please assess the completion status of the following clinical trial:

Trial Title: Phase 1 Study to Compare CMAB807 Injection to Prolia® in Healthy Volunteers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Fully understand and voluntary sign the informed consent form,and be able to complete the study according to the protocol;~* 18 years ≤ age ≤65 years;~* Physical examination, vital signs, clinical laboratory examination and various examinations are normal or abnormal without clinical significance;~* Agree to take effective contraceptive measures throughout the study period (including not limited to: physical contraception, hormonal drugs of pregnancy, surgery, abstinence, etc.,) until at least 10 months after the last study is administered;~* Body weight ≥50 kg, 19kg/m2≤BMI≤26kg/m2;~* Serum calcium level between 2.15\~2.55mmol/L（including the boundary value）;~* Normal or clinically acceptable electrocardiogram (12-lead ECG), QTcB\<450msec.~Exclusion Criteria:~* Drink 14 units of alcohol per week within 3 months prior to administration, or take any alcohol substance within 48 hours before subcutaneous injection;~* Substance abuse within 5 years before subcutaneous injection;~* Smoke more than 5 cigarettes per day or the same amount of tobacco within 3 months before subcutaneous injection;~* Allergic constitution;~* Drink excessive amounts of tea, coffee or caffeinated beverages within 30 days before subcutaneous injection;~* Use any prescription, over-the-counter, vitamin or herbal medicine within 30 days before subcutaneous injection;~* Bone surgery was performed within 30 days before administration;~* History of osteomyelitis or osteonecrosis of the jaw;~* Inflammation or abnormalities in or around the site of administration;~* Needle or blood sickness;~* Dental disease or jaw disease requiring oral surgery, dental surgery; or plan to have dental surgery during the study;~* Received the study drug(including Xgeva and Prolia), or participated in a clinical trial within 3 months prior to administration；~* Received living viraL vaccine within 3 months prior to administration;~* Blood donation or blood loss \>400ml within 3 months prior to administration;~* Hepatitis B surface antigen was positive, and/or hepatitis C antibody was positive;~* The HIV antibody test was not negative;~* Syphilitic test was positive;~* Drug was detected in the urine;~* Hyperparathyroidism, hypothyroidism, rheumatoid arthritis, Ankylosing Spondylitis, osteomalacia, Paget's disease, or fracture within 6 months;~* History of severe lumbar disc herniation;~* Insanity or legal problem are exist;~* Plan to engage in strenuous physical labor or exercise during the study;~* Other conditions that made it difficult to participate the study.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- CMAB807 (Type: EXPERIMENTAL): 60mg by subcutaneous injection once on the first day.
- Prolia® (Type: ACTIVE_COMPARATOR): 60mg by subcutaneous injection once on the first day.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete